Prevalence of gastroduodenal ulcers/erosions in patients taking low-dose aspirin with either 15 mg/day of lansoprazole or 40 mg/day of famotidine: The OITA-GF study 2

BMC Research Notes

Junichi Kadota²  Kazunari Murakami¹  Akira Tamura² 

[1]General Medicine, Oita University, Yufu, Japan

[2]Internal Medicine 2, Oita University, Yufu, Japan

关键词: Lansoprazole;    Famotidine;    Gastroduodenal ulcer;    Gastroduodenal erosion;    Aspirin;   

Others  :  1143147
DOI  :  10.1186/1756-0500-6-116

 received in 2012-11-23, accepted in 2013-03-20,  发布年份 2013

【 摘 要 】

Background

The preventive effects of histamine 2 receptor antagonists vs. proton pump inhibitors on low-dose aspirin (LDA)-related gastroduodenal mucosal injury have not been fully investigated. We conducted a cross-sectional study to compare the prevalence of gastroduodenal ulcers or erosions in patients taking LDA with either 40 mg/day of famotidine or 15 mg/day of lansoprazole for at least three months.

Methods

Of 84 eligible patients, two taking 40 mg/day of famotidine and four taking 15 mg/day of lansoprazole refused to undergo upper gastrointestinal endoscopy. Ultimately, we performed upper gastrointestinal endoscopy in 78 patients taking either 40 mg/day of famotidine (group F, n = 31) or 15 mg/day of lansoprazole (group L, n = 47). The prevalence of gastroduodenal ulcers or erosions and the magnitude of gastric mucosal injury evaluated using modified Lanza scores were compared between the two groups.

Results

No patients in either group had gastroduodenal ulcers. Gastroduodenal erosions were more prevalent in group F than in group L (48.4% vs. 17.0%, p = 0.005). The modified Lanza scores (mean ± SD) were significantly higher in group F than in group L (0.9 ± 1.3 vs. 0.3 ± 0.7, p = 0.007). A multivariate logistic regression analysis showed that the use of lansoprazole was negatively associated with gastroduodenal erosions.

Conclusions

This study suggests that 15 mg/day of lansoprazole may be more effective in preventing the development of LDA-related gastroduodenal erosions than 40 mg/day of famotidine. The preventive effects of these two regimens on the development of LDA-related gastroduodenal ulcers require further investigation.

【 授权许可】

   
2013 Tamura et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, Hochman JS, Krumholz HM, Lamas GA, Mullany CJ, Pearle DL, Sloan MA, Smith SC Jr, Anbe DT, Kushner FG, Ornato JP, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW, 2004 Writing Committee Members: 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American college of cardiology/American heart association task force on practice guidelines: developed in collaboration with the Canadian cardiovascular society endorsed by the American academy of family physicians: 2007 writing group to review new evidence and update the ACC/AHA 2004 guidelines for the management of patients with ST-elevationmyocardial infarction, writing on behalf of the 2004 writing committee. Circulation 2008, 2008(117):296-329.
• [2]Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B: ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American college of cardiology/American heart association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction) developed in collaboration with the American college of emergency physicians, the society for cardiovascular angiography and interventions, and the society of thoracic surgeons, endorsed by the American association of cardiovascular and pulmonary rehabilitation and the society for academic emergency medicine. J Am Coll Cardiol 2007, 50:e1-e157.
• [3]Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, Rawlins M, Vessey M, Wainwright P: Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995, 310:827-830.
• [4]Sørensen HT, Mellemkjaer L, Blot WJ, Nielsen GL, Steffensen FH, McLaughlin JK, Olsen JH: Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000, 95:2218-2224.
• [5]Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM: ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American college of cardiology foundation task force on clinical expert consensus documents. Circulation 2008, 118:1894-1909.
• [6]Taha AS, McCloskey C, Prasad R, Bezlyak V: Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 2009, 374:119-125.
• [7]Nishino M, Sugimoto M, Kodaira C, Yamade M, Uotani T, Shirai N, Ikuma M, Tanaka T, Sugimura H, Hishida A, Furuta T: Preventive effects of lansoprazole and famotidine on gastric mucosal injury induced by low-dose aspirin in Helicobacter pylori-negative healthy volunteers. J Clin Pharmacol 2011, 51:1079-1086.
• [8]Ng FH, Wong SY, Lam KF, Chu WM, Chan P, Ling YH, Kng C, Yuen WC, Lau YK, Kwan A, Wong BC: Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology 2010, 138:82-88.
• [9]Holtmann G, Gschossmann J, Buenger L, Gerken G, Talley NJ: Do changes in visceral sensory function determine the development of dyspepsia during treatment with aspirin? Gastroenterology 2002, 123:1451-1458.
• [10]Yeomans ND, Lanas AI, Talley NJ, Thomson AB, Daneshjoo R, Eriksson B, Appelman-Eszczuk S, Långström G, Naesdal J, Serrano P, Singh M, Skelly MM, Hawkey CJ: Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005, 22:795-801.
• [11]Tamura A, Murakami K, Kadota J, OITA-GF Study Investigators: Prevalence and independent factors for gastroduodenal ulcers/erosions in asymptomatic patients taking low-dose aspirin and gastroprotective agents: the OITA-GF study. QJM 2011, 104:133-139.
• [12]Dimenäs E, Glise H, Hallerbäck B, Hernqvist H, Svedlund J, Wiklund I: Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol 1993, 28:681-687.
• [13]Katsuragi K, Noda A, Tachikawa T, Azuma A, Mukai F, Murakami K, Fujioka T, Kato M, Asaka M: Highly sensitive urine-based enzyme-linked immunosorbent assay for detection of antibody to Helicobacter pylori. Helicobacter 1998, 3:289-295.
• [14]Kato M, Asaka M, Saito M, Sekine H, Ohara S, Toyota T, Akamatsu T, Kaneko T, Kiyosawa K, Nishizawa O, Kumagai T, Katsuyama T, Abe M, Kosaka M, Hariya S, Minami K, Sanai Y, Sawamura M, Tachikawa T: Clinical usefulness of urine-based enzyme-linked immunosorbent assay for detection of antibody to Helicobacter pylori: a collaborative study in nine medical institutions in Japan. Helicobacter 2000, 5:109-119.
• [15]Yamao J, Kikuchi E, Matsumoto M, Nakayama M, Ann T, Kojima H, Mitoro A, Yoshida M, Yoshikawa M, Yajima H, Miyauchi Y, Ono H, Akiyama K, Sakurai G, Kinoshita Y, Haruma K, Takakura Y, Fukui H: Assessing the efficacy of famotidine and rebamipide in the treatment of gastric mucosal lesions in patients receiving long-term NSAID therapy (FORCE–famotidine or rebamipide in comparison by endoscopy). J Gastroenterol 2006, 41:1178-1185.
• [16]Brodie DA, Chase BJ: Role of gastric acid in aspirin-induced gastric irritation in the rat. Gastroenterology 1967, 53:604-610.
• [17]Nishino M, Sugimoto M, Kodaira C, Yamade M, Shirai N, Ikuma M, Tanaka T, Sugimura H, Hishida A, Furuta T: Relationship between low-dose aspirin-induced gastric mucosal injury and intragastric pH in healthy volunteers. Dig Dis Sci 2010, 55:1627-1636.
• [18]Bell NJ, Hunt RH: Progress with proton pump inhibition. Yale J Biol Med 1992, 65:649-657.
• [19]Scheiman JM, Devereaux PJ, Herlitz J, Katelaris PH, Lanas A, Veldhuyzen van Zanten S, Nauclér E, Svedberg LE: Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart 2011, 97:797-802.
• [20]Laine L, Weinstein WM: Subepithelial hemorrhages and erosions of human stomach. Dig Dis Sci 1988, 33:490-503.
• [21]Silverstein FE, Gilbert DA, Tedesco FJ, Buenger NK, Persing J: The national ASGE survey on upper gastrointestinal bleeding. II. Clinical prognostic factors. Gastrointest Endosc 1981, 27:80-93.
• [22]Cappell MS: The safety and clinical utility of esophagogastroduodenoscopy for acute gastrointestinal bleeding after myocardial infarction: a six-year study of 42 endoscopies in 34 consecutive patients at two university teaching hospitals. Am J Gastroenterol 1993, 88:344-350.
• [23]Toljamo KT, Niemelä SE, Karttunen TJ, Karvonen AL, Lehtola JK: Clinical significance and outcome of gastric mucosal erosions: a long-term follow-up study. Dig Dis Sci 2006, 51:543-537.
• [24]Hawkey CJ, Laine L, Harper SE, Quan HU, Bolognese JA, Mortensen E, Rofecoxib Osteoarthritis Endoscopy Multinational Study Group: Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. Aliment Pharmacol Ther 2001, 15:1593-1601.